Incretin hormones and insulin sensitivity. Trends Endocrinol Metab 2005;16(4):135-6
Date
04/30/2005Pubmed ID
15860408DOI
10.1016/j.tem.2005.03.002Scopus ID
2-s2.0-18044386757 (requires institutional sign-in at Scopus site) 18 CitationsAbstract
Incretin hormones such as glucagon-like peptide-1 (GLP-1) and the longer lasting analog exendin-4 show clinical promise for the treatment of diabetes because of glucoregulatory activities that enhance beta-cell function and growth, and actions in the central nervous system that induce satiety and decrease caloric intake. The actions of these peptides on insulin-responsive tissues is less clear, but recent advances indicate that chronic treatment with exendin-4 increases insulin sensitivity via two distinct mechanisms: one is attributable to changes in food intake and the subsequent improvements in glycemia; the second is largely independent of reductions in blood glucose. In addition, exendin-4 might also have direct effects on beta-cell neogenesis that are independent of insulin demand.
Author List
Hansen PA, Corbett JAAuthor
John A. Corbett PhD Professor in the Biochemistry department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsDiabetes Mellitus
Glucagon
Glucagon-Like Peptide 1
Humans
Insulin
Insulin Resistance
Peptide Fragments
Peptides
Protein Precursors
Venoms
